Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Frequency- and Intensity-Dependent After-Effects of High-Definition Transcranial Alternating Current Stimulation on Resting-State Electroencephalography

29. august 2026 opdateret af: Haifeng Jiang, Shanghai Mental Health Center

Frequency- and Intensity-Dependent After-Effects of High-Definition Transcranial Alternating Current Stimulation on Resting-State Electroencephalography in Patients With Auditory Hallucinations and Healthy Controls

This study aims to investigate the after-effects of high-definition transcranial alternating current stimulation (HD-tACS) with varying parameters on resting-state brain activity in patients with schizophrenia experiencing auditory hallucinations.

Studieoversigt

Status

Status

Angiver den aktuelle rekrutteringsstatus eller den udvidede adgangsstatus.
Afsluttet

Betingelser

Betingelser

Den sygdom, lidelse, syndrom, sygdom eller skade, der undersøges. På ClinicalTrials.gov kan tilstande også omfatte andre sundhedsrelaterede problemer, såsom levetid, livskvalitet og sundhedsrisici.

Intervention / Behandling

Intervention / Behandling

En proces eller handling, der er i fokus for en klinisk undersøgelse. Interventioner omfatter lægemidler, medicinsk udstyr, procedurer, vacciner og andre produkter, der enten er til undersøgelse eller allerede er tilgængelige. Interventioner kan også omfatte ikke-invasive tilgange, såsom uddannelse eller ændring af kost og motion.

Undersøgelsestype

Undersøgelsestype

Beskriver karakteren af ​​en klinisk undersøgelse. Undersøgelsestyper omfatter interventionelle undersøgelser (også kaldet kliniske forsøg), observationsundersøgelser (herunder patientregistre) og udvidet adgang.
Interventionel

Tilmelding (Faktiske)

Tilmelding

Antallet af deltagere i en klinisk undersøgelse. Den "forventede" tilmelding er det mål for antallet af deltagere, som forskerne skal bruge til undersøgelsen.
36

Fase

Fase

Stadiet af et klinisk forsøg, der studerer et lægemiddel eller et biologisk produkt, baseret på definitioner udviklet af U.S. Food and Drug Administration (FDA). Fasen tager udgangspunkt i undersøgelsens formål, antallet af deltagere og andre karakteristika. Der er fem faser: Tidlig fase 1 (tidligere opført som fase 0), fase 1, fase 2, fase 3 og fase 4. Ikke relevant bruges til at beskrive forsøg uden FDA-definerede faser, herunder forsøg med enheder eller adfærdsmæssige indgreb.
  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Kina
      • Fuyang, Kina
        • Fuyang Mental Heath Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Berettigelseskriterier

De nøglekrav, som personer, der ønsker at deltage i et klinisk studie, skal opfylde eller de egenskaber, de skal have. Kvalifikationskriterier består af både inklusionskriterier (som er nødvendige for at en person kan deltage i undersøgelsen) og eksklusionskriterier (som forhindrer en person i at deltage). Typer af berettigelseskriterier omfatter, om en undersøgelse accepterer raske frivillige, har alders- eller aldersgruppekrav eller er begrænset af køn.

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Age 18 to 65 years;
  • Meet the diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5);
  • Adequate verbal communication skills;
  • At least one auditory hallucination episode within the past week;
  • Willing to participate in the study and able to complete all trial procedures.

Exclusion Criteria:

  • History of neurological disorders, severe physical illness, traumatic brain injury, or craniotomy;
  • History of epileptic seizures or other neuropsychiatric disorders;
  • At risk for suicide, self-injury, or impulsive behavior.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm

Deltagergruppe / Arm

En gruppe eller undergruppe af deltagere i et klinisk forsøg, der modtager en specifik intervention/behandling eller ingen intervention i henhold til forsøgets protokol.
Intervention / Behandling

Intervention / Behandling

En proces eller handling, der er i fokus for en klinisk undersøgelse. Interventioner omfatter lægemidler, medicinsk udstyr, procedurer, vacciner og andre produkter, der enten er til undersøgelse eller allerede er tilgængelige. Interventioner kan også omfatte ikke-invasive tilgange, såsom uddannelse eller ændring af kost og motion.
Eksperimentel: 0.4mA-10Hz HD-tACS
For 0.4mA-10Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 0.4mA-20Hz HD-tACS
For 0.4mA-20Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 20 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 0.4mA-40Hz HD-tACS
For 0.4mA-40Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 20 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 0.4mA-140Hz HD-tACS
For 0.4mA-140Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 1mA-10Hz HD-tACS
For 1mA-10Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 1mA-20Hz HD-tACS
For 1mA-20Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 1mA-40Hz HD-tACS
For 1mA-40Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 1mA-140Hz HD-tACS
For 1mA-140Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 2mA-10Hz HD-tACS
For 2mA-10Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 2mA-20Hz HD-tACS
For 2mA-20Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 2mA-40Hz HD-tACS
For 2mA-40Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: 2mA-140Hz HD-tACS
For 2mA-140Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.
Enhed: high-definition transcranial alternating current stimulation(HD-tACS)
The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.
Eksperimentel: sham HD-tACS
For sham HD-tACS, we will stimulate the personalized left or right temporal lobe channel using sham HD-tACS pattern.
Enhed: sham high-definition transcranial alternating current stimulation(HD-tACS)
The sham intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. To mimic the sensory experience of active stimulation, the sham condition includes a 10-second ramp-up and a 5-second ramp-down period at 0.4 mA and 140 Hz, with no current delivered during the intervening 90-second period.

Hvad måler undersøgelsen?

Primære resultatmål

Primære resultatmål

I et klinisk studies protokol er det planlagte resultatmål, der er det vigtigste for at evaluere effekten af ​​en intervention/behandling. De fleste kliniske undersøgelser har ét primært resultatmål, men nogle har mere end ét.
Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Beta2-band EEG power at the stimulation site
Tidsramme: 180-second recording after each 90-second stimulation
Changes in EEG power(dB) in beta2 band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation

Sekundære resultatmål

Sekundære resultatmål

I en klinisk undersøgelses protokol er et planlagt resultatmål, der ikke er lige så vigtigt som det primære resultatmål for at evaluere effekten af ​​en intervention, men som stadig er af interesse. De fleste kliniske undersøgelser har mere end ét sekundært resultatmål.
Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Alpha-band EEG power at the stimulation site
Tidsramme: 180-second recording after each 90-second stimulation
Changes in EEG power(dB) in alpha band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation
Delta-band EEG power at the stimulation site
Tidsramme: 180-second recording after each 90-second stimulation
Changes in EEG power(dB) in delta band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation
Theta-band EEG power at the stimulation site
Tidsramme: 180-second recording after each 90-second stimulation
Changes in EEG power(dB) in theta band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation
Gamma-band EEG power at the stimulation site
Tidsramme: 180-second recording after each 90-second stimulation
Changes in EEG power(dB) in gamma band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation
Beta2-band functional connectivity measured by EEG wPLI
Tidsramme: 180-second recording after each 90-second stimulation
Beta2-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation
Alpha-band functional connectivity measured by EEG wPLI
Tidsramme: 180-second recording after each 90-second stimulation
Alpha-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation
Delta-band functional connectivity measured by EEG wPLI
Tidsramme: 180-second recording after each 90-second stimulation
Delta-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation
Theta-band functional connectivity measured by EEG wPLI
Tidsramme: 180-second recording after each 90-second stimulation
Theta-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation
Gamma-band functional connectivity measured by EEG wPLI
Tidsramme: 180-second recording after each 90-second stimulation
Gamma-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.
180-second recording after each 90-second stimulation

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Sponsor

Den organisation eller person, der igangsætter undersøgelsen, og som har myndighed og kontrol over undersøgelsen.
Shanghai Mental Health Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

Studiestart

Den faktiske dato, hvor den første deltager blev tilmeldt en klinisk undersøgelse. Den "forventede" undersøgelses startdato er den dato, som forskerne tror vil være undersøgelsens startdato.
5. december 2025

Primær færdiggørelse (Faktiske)

Primær færdiggørelse

Den dato, hvor den sidste deltager i et klinisk studie blev undersøgt eller modtog en intervention for at indsamle endelige data for det primære resultatmål. Hvorvidt det kliniske studie sluttede i henhold til protokollen eller blev afsluttet, påvirker ikke denne dato. For kliniske undersøgelser med mere end ét primært resultatmål med forskellige afslutningsdatoer refererer dette udtryk til den dato, hvor dataindsamlingen er afsluttet for alle de primære resultatmål. Den "forventede" primære afslutningsdato er den dato, som forskerne tror vil være den primære afslutningsdato for undersøgelsen.
11. februar 2026

Studieafslutning (Faktiske)

Studieafslutning

Den dato, hvor den sidste deltager i et klinisk studie blev undersøgt eller modtog en intervention/behandling for at indsamle endelige data for de primære resultatmål, sekundære udfaldsmål og uønskede hændelser (det vil sige den sidste deltagers sidste besøg). Den "forventede" undersøgelses afslutningsdato er den dato, som forskerne tror vil være undersøgelsens afslutningsdato.
15. februar 2026

Datoer for studieregistrering

Først indsendt

Først indsendt

Den dato, hvor undersøgelsens sponsor eller investigator første gang indsendte en undersøgelsespost til ClinicalTrials.gov. Der er typisk en forsinkelse på et par dage mellem den første indsendte dato og postens tilgængelighed på ClinicalTrials.gov (den første offentliggjorte dato).
1. juli 2026

Først indsendt, der opfyldte QC-kriterier

Først indsendt, der opfyldte QC-kriterier

Den dato, hvor undersøgelsens sponsor eller investigator første gang indsender en undersøgelsespost, der er i overensstemmelse med National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgangskriterier. Sponsoren eller investigatoren skal muligvis revidere og indsende en undersøgelsespost en eller flere gange, før NLM's kvalitetskontrolkriterier er opfyldt. Det er sponsorens eller investigatorens ansvar at sikre, at undersøgelsesposten er i overensstemmelse med NLM QC-gennemgangskriterierne.
29. august 2026

Først opslået (Faktiske)

Først opslået

Datoen, hvor undersøgelsesposten først var tilgængelig på ClinicalTrials.gov efter National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgang er afsluttet. Der er typisk en forsinkelse på et par dage mellem den dato, hvor undersøgelsens sponsor eller investigator indsendte undersøgelsesposten, og den første offentliggjorte dato.
1. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

Sidste opdatering sendt

Den seneste dato, hvor ændringer i en undersøgelsespost blev gjort tilgængelig på ClinicalTrials.gov. Der kan være en forsinkelse mellem det tidspunkt, hvornår ændringerne blev indsendt til ClinicalTrials.gov af undersøgelsens sponsor eller investigator (datoen for sidste opdatering afsendt) og den sidste opdatering, der blev sendt.
1. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Den seneste dato, hvor undersøgelsens sponsor eller investigator indsendte ændringer til en undersøgelsespost, der er i overensstemmelse med National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgangskriterier. Det er sponsorens eller investigatorens ansvar at sikre, at undersøgelsesposten er i overensstemmelse med NLM QC-gennemgangskriterierne.
29. august 2026

Sidst verificeret

Sidst verificeret

Den seneste dato, hvor undersøgelsens sponsor eller investigator bekræftede oplysningerne om en klinisk undersøgelse på ClinicalTrials.gov som nøjagtige og aktuelle. Hvis en undersøgelse med rekrutteringsstatus som rekruttering; rekrutterer endnu ikke; eller aktiv, ikke rekruttering er ikke blevet bekræftet inden for de seneste 2 år, er undersøgelsens rekrutteringsstatus vist som ukendt.
1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

Andre undersøgelses-id-numre

Andre identifikatorer eller ID-numre end NCT-nummeret, der er tildelt til en klinisk undersøgelse af undersøgelsens sponsor, finansieringsgivere eller andre. Disse numre kan omfatte unikke identifikatorer fra andre forsøgsregistre og National Institutes of Health-bevillingsnumre.
  • HFJiang-006

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data will not be made publicly available because of privacy and confidentiality considerations related to the collection of electrophysiological data from human participants.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Cookieindstillinger

Vi bruger cookies for at sikre, at vi giver dig den bedste oplevelse på vores hjemmeside. For flere detaljer skal du læse omhyggeligt vores Politik om beskyttelse af personlige oplysninger og cookies. ...>>>Du kan når som helst ændre dine præferencer eller trække dit samtykke tilbage ved at slette cookies fra din hjemmeside eller computer som beskrevet i politikken. Accepter det og vælg dine præferencer ved at markere de tilsvarende felter i afsnittet "Administrer indstillinger" nedenfor. Læs vores servicevilkår omhyggeligt, inden du fortsætter med at bruge nogen del af dette websted.
«Administrer indstillinger